Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male caucasian volunteers

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 1, 2006, Pages 33-39

  Domagala, Florence ^a,d   Ficheux, Hervé ^a   Houin, Georges ^b   Barré, Jérôme ^c  

^a NEGMA GILD   (France)

^b CHU RANGUEIL   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d NONE   (France)

Author keywords

CAS 113712 98 4; Proton pump inhibitor; Tenatoprazole, dose linearity, human pharmacokinetics

Indexed keywords

BENATOPRAZOLE; CYTOCHROME P450 2C19; DRUG METABOLITE; PROTON PUMP INHIBITOR; SULFIDE; SULFONE; TU 501; TU 502; TU 505; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG URINE LEVEL; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LINEAR SYSTEM; MALE; MASS SPECTROMETRY; MULTIPLE DRUG DOSE; NORMAL HUMAN; SINGLE DRUG DOSE; STEADY STATE;

EID: 31444443717     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296698     Document Type: Article

References (16)

1. Wallmark, B., Larsson, H., Humble, L., The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J. Biol. Chem. 260, 13681 (1985)
2. +)-ATPase. Nature 290, 159 (1981)
3. Lindberg, P., Brandstrom, A., Wallmark, B. et al., Omeprazole: the first proton pump inhibitor. Med. Res. Rev. 10, 1 (1990)
4. Sachs, G., Shin, J. M., Besancon, M. et al., The continuing development of gastric acid pump inhibitors. Aliment. Pharmacol. Ther. 7 (Suppl. 1), 4 (1993)
5. Sachs, G., Shin, J. M., Briving, C. et al., The pharmacology of the gastric acid pump: the H+,K+ ATPase. Ann. Rev. Pharmacol. Toxicol. 35, 277 (1995)
6. Wallmark, B., Jaresten, B. M., Larsson, H. et al., Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN- on gastric acid secretion. Am. J. Physiol. 245, G64 (1983)
7. +)-ATPase by omeprazole. Biochim. Biophys. Acta 817, 25 (1985)
8. Uchiyama, K., Wakatsuki, D., Kakinoki, B. et al., Effects of tenatoprazole, a novel H+,K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find. Exp. Clin. Pharmacol. 21, 115 (1999)
9. Uchiyama, K., Wakatsuki, D., Kakinoki, B. et al., The long-lasting effect of tenatoprazole, a novel H+,K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J. Pharm. Pharmacol. 51, 457 (1999)
10. Goldstein, J. A., Ishizaki, T., Chiba, K. et al., Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59 (1997)
11. Lind, T., Cederberg, C., Ekenved, G. et al., Effect of Omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 24, 270 (1983)
12. Londong, W., Londong, V., Cederberg, C. et al., Dose-response study of Omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 85, 1373 (1983)
13. Sachs, G., Improving on PPI-based therapy of GORD. Eur. J. Gastroenterol. Hepatol. 13 (Suppl 1), S35 (2001)
14. Bell, N., Karol, M. D., Sachs, G. et al., Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment. Pharmacol. Ther. 15, 105 (2001)
15. Jansen, J. B., Lundborg, P., Baak, L. C. et al., Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 29, 75 (1988)
16. Andersson, T., Cederberg, C., Regardh, C. G. et al., Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur. J. Clin. Pharmacol. 39, 195 (1990)